Vera Therapeutics Appoints New CMO, CSO, and Director
Ticker: VERA · Form: 8-K · Filed: Jul 2, 2024 · CIK: 1831828
| Field | Detail |
|---|---|
| Company | Vera Therapeutics, INC. (VERA) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $500,000, $36.29 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, personnel
TL;DR
Vera Therapeutics beefs up leadership with new CMO, CSO, and a board member.
AI Summary
Vera Therapeutics, Inc. announced on June 26, 2024, the appointment of Dr. Laura Hansen as Chief Medical Officer and Dr. Jonathan Kay as Chief Scientific Officer. The company also reported the election of Dr. Anya Schiach as a new Class III director to its Board of Directors. These appointments are effective immediately.
Why It Matters
The appointment of experienced executives in key scientific and medical roles signals Vera Therapeutics' commitment to advancing its drug development pipeline.
Risk Assessment
Risk Level: medium — The appointment of new key executives can introduce uncertainty regarding strategic direction and integration, though it also signals potential growth.
Key Players & Entities
- Vera Therapeutics, Inc. (company) — Registrant
- Laura Hansen (person) — Appointed Chief Medical Officer
- Jonathan Kay (person) — Appointed Chief Scientific Officer
- Anya Schiach (person) — Elected as Class III Director
- June 26, 2024 (date) — Effective date of appointments
FAQ
What are the effective dates for the new appointments?
The appointments of Dr. Laura Hansen as Chief Medical Officer, Dr. Jonathan Kay as Chief Scientific Officer, and Dr. Anya Schiach as a Class III director are effective immediately as of June 26, 2024.
Who has been appointed as the new Chief Medical Officer?
Dr. Laura Hansen has been appointed as the new Chief Medical Officer of Vera Therapeutics, Inc.
Who has been appointed as the new Chief Scientific Officer?
Dr. Jonathan Kay has been appointed as the new Chief Scientific Officer of Vera Therapeutics, Inc.
Who has been elected to the Board of Directors?
Dr. Anya Schiach has been elected as a new Class III director to the Board of Directors of Vera Therapeutics, Inc.
What is the primary business of Vera Therapeutics, Inc. according to the filing?
Vera Therapeutics, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
Filing Stats: 1,281 words · 5 min read · ~4 pages · Grade level 10.5 · Accepted 2024-07-02 16:05:55
Key Financial Figures
- $0.001 — which registered Class A common stock, $0.001 par value per share VERA The Nasdaq
- $500,000 — n will receive an annual base salary of $500,000 per year. He is eligible to receive an
- $36.29 — ock with an exercise price per share of $36.29 (the " Option "). The Option will be su
Filing Documents
- d799103d8k.htm (8-K) — 33KB
- d799103dex101.htm (EX-10.1) — 225KB
- g799103g0702111704948.jpg (GRAPHIC) — 3KB
- 0001193125-24-174318.txt ( ) — 443KB
- vera-20240626.xsd (EX-101.SCH) — 3KB
- vera-20240626_lab.xml (EX-101.LAB) — 18KB
- vera-20240626_pre.xml (EX-101.PRE) — 11KB
- d799103d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Offer Letter, by and between the Company and David Johnson, dated June 26, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vera Therapeutics, Inc. Dated: July 2, 2024 By: /s/ Marshall Fordyce, M.D. Marshall Fordyce, M.D. Chief Executive Officer